Abzyme Therapeutics

What Abzyme Therapeutics does

Abzyme Therapeutics is a private biopharmaceutical company founded in 2010 and headquartered in Royersford, Pennsylvania. The company is focused on developing modular single domain VHH antibody fragments for use in immunotherapy applications. VHH fragments, derived from camelid heavy-chain-only antibodies, are small-format binding proteins that offer advantages such as improved tissue penetration, thermal stability, and modularity for engineering multi-specific constructs — properties relevant to next-generation immuno-oncology and immune-modulation therapeutics.

The company operates with a very small team of 1-10 employees under the scientific leadership of co-founder and Chief Scientific Officer Hiep Tran. The corporate website (abzymetx.com) was inaccessible at the time of data collection, returning only a verification/waiting page, and no detailed product pipeline, patents, partnerships, clinical milestones, or funding history were disclosed in the available data. There is no indication of an in-licensed or partnered program, no disclosed IND-enabling work, and no evidence of commercial revenue, licensing income, or third-party collaborations.

The business model cannot be definitively characterized from the input. As a private, small-cap preclinical-stage biotech with no disclosed funding rounds, partnerships, or revenue, Abzyme appears to be sustained by founder capital, potential non-dilutive grant funding, or undisclosed angel/seed investment. No pricing models, GTM motion, customer segments, or distribution channels are articulated in the source material. The company serves the biopharmaceutical R&D ecosystem as a potential pipeline developer or licensor of VHH-based therapeutic candidates, but downstream customer relationships, target indications, and development stage remain unconfirmed.

Name

Abzyme Therapeutics

Website

https://abzymetx.com

Company type

Private

Founded year

2010

Headcount range

1–10 employees

Short description

Abzyme Therapeutics is a private, preclinical-stage biopharmaceutical company founded in 2010 in Royersford, Pennsylvania, developing modular single domain VHH antibody fragments for immunotherapy applications under the scientific leadership of co-founder and CSO Hiep Tran.

Ownership category

akta.pro rank

Product category

Therapeutic Antibodies

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)

akta.pro secondary industry

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE)

Keywords

• Single domain antibodies
• VHH antibody fragments
• Antibody therapeutics
• Immunotherapy development
• Biopharmaceutical research

Headquarters

HQ city

Royersford

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D

Core offering

Abzyme Therapeutics is a biopharmaceutical company focused on developing modular single domain VHH antibody fragments for immunotherapy applications. The company works on engineering camelid-derived antibody fragments as therapeutic candidates for immune-related disease targets.

Differentiator

Problem solved

Functional benefit

Products and services

• Modular VHH Antibody Fragments

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Others

• Adimab: Leader in antibody discovery and engineering with a proprietary yeast-based platform serving pharma partners. Comparable as a platform-based antibody discovery company, though it operates as a service/discovery partner rather than a therapeutic developer.

Broad incumbents

• Ablynx (Sanofi): The originator of the VHH/nanobody platform (now part of Sanofi following the 2018 acquisition). Highly comparable technology foundation; competes broadly with Abzyme in the same molecular modality space.
• ImmunoGen: Antibody-drug conjugate pioneer with multiple clinical-stage programs. Adjacent to Abzyme's VHH immunotherapy focus because nanobodies are increasingly used as targeting arms of next-generation ADCs.
• Genmab: Major antibody therapeutics company behind multiple approved products (DARZALEX, etc.) with proprietary antibody platforms (DuoBody, HexaBody). Comparable therapeutic-area focus, with a broader, more mature platform portfolio.
• MacroGenics: Clinical-stage biotech developing multi-specific antibody therapeutics for cancer and autoimmune disease. Comparable in therapeutic area (immunotherapy) and antibody-engineering platform approach.

Emerging players

• Elasmogen: Aberdeen-based preclinical-stage developer of soloMER (humanized VHH) therapeutics. Comparable in modality and scale to Abzyme as an early-stage VHH platform.
• Compass Therapeutics: Clinical-stage biotech developing multi-specific antibodies for immuno-oncology. Comparable as a smaller-platform antibody company pursuing modular multi-specific immunotherapies.

Direct peers

• Harbour BioMed: Clinical-stage biotech with a heavy VHH/nanobody franchise (HBM7008 and batoclimab). Closely aligned with Abzyme in platform modality and immunology/immuno-oncology focus.
• Argenx: The leading clinical-stage VHH/nanobody platform company (efgartigimod / VYVGART). Directly comparable to Abzyme as both are built on VHH single-domain antibody technology for immunology indications, though Argenx is a commercial-stage incumbent.
• Crescendo Biologics: UK-based developer of VHH-based T-cell engagers and immune modulators. Directly comparable as a VHH-platform biotech pursuing multi-specific immunotherapies.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Abzyme Therapeutics